Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Contra].

Deutsche medizinische Wochenschrift (1946) - 1 Mar 2012

von Pawel J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to ErbB Receptors
Share to EGFR gene
Share to Genes, erbB-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Palliative Care

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 22415623
DOI: 10.1055/s-0031-1298877

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Contra].PMID 22415623Read ↗

[Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Pro].Semantic proximity Read ↗

Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.Semantic proximity Read ↗

Counterpoint: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? No.Semantic proximity Read ↗

[Treatment choice after EGFR-TKI resistance].Semantic proximity Read ↗

Optimising therapy for EGFR-addicted NSCLC: just the start.Semantic proximity Read ↗

Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?Semantic proximity Read ↗

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?Semantic proximity Read ↗

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations.Semantic proximity Read ↗

[Searching for EGFR: current practices].Semantic proximity Read ↗

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients.Semantic proximity Read ↗

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in PracticeSemantic proximity Read ↗

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.